Adrenomed Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 26

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $749K

  • Investors
  • 9

Adrenomed General Information

Description

Developer of clinical-stage pharmaceutical products designed to improve vascular integrity easily. The company's products use biomarker-guided monoclonal antibody therapies which offer causative and safe treatment of acute circulatory failure, enabling doctors to reduce vascular leakage, stabilize the circulation, and lower mortality.

Contact Information

Website
www.adrenomed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Neuendorfstraße 15A
  • 16761 Hennigsdorf
  • Germany
+49 03302 000000
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Neuendorfstraße 15A
  • 16761 Hennigsdorf
  • Germany
+49 03302 000000

Adrenomed Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adrenomed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 20-Feb-2024 $749K 000.00 Completed Generating Revenue
5. Later Stage VC 05-Jul-2022 00.000 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 30-Aug-2021 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series E) 23-Mar-2021 000.00 000.00 00000 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series D) 17-Jun-2020 $30.2M $30.2M 000.00 Completed Clinical Trials - Phase 1
1. Later Stage VC 01-Jan-2014 Completed Clinical Trials - Phase 1
To view Adrenomed’s complete valuation and funding history, request access »

Adrenomed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of clinical-stage pharmaceutical products designed to improve vascular integrity easily. The company's product
Drug Discovery
Hennigsdorf, Germany
26 As of 2024
000.00
0000000000 0 000.00

000000

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nost
0000 000000000
Sunnyvale, CA
0 As of 0000
00.000
0000000000 00.000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
San Diego, CA
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adrenomed Competitors (60)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Altravax Formerly VC-backed Sunnyvale, CA 0 00.000 0000000000 00.000
Viriom Venture Capital-Backed San Diego, CA 0 000.00 0000000000 0 000.00
Cardior Formerly VC-backed Hannover, Germany 00 00000 000000&0 00000
AgomAb Venture Capital-Backed Antwerp, Belgium 00 00000 00000000000 00000
Cardurion Venture Capital-Backed Burlington, MA 00 00000 00000000000 00000
You’re viewing 5 of 60 competitors. Get the full list »

Adrenomed Patents

  • 88

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 46

    Granted

  • 34

    Pending

  • 000

    Expiring in next 12 mo

Adrenomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4345109-A1 Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease Inactive 30-Sep-2022 000000000 0
CA-3207969-A1 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock and prediction of an increase of dpp3 in a critically ill patient Pending 29-Jul-2022
US-20210285949-A1 Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin Pending 16-Mar-2020 000000000 0
AU-2021238591-A1 Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin Pending 16-Mar-2020 000000000
CA-3112051-A1 Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin Pending 16-Mar-2020 C07K16/22
To view Adrenomed’s complete patent history, request access »

Adrenomed Executive Team (17)

Name Title Board Seat
Richard Jones Ph.D Chief Executive Officer & Chairman
David Germonpré Chief Financial Officer
Bernd Wegener Co-Founder & Member of Supervisory Board
Gerald Moeller Co-Founder & Member of Supervisory Board
Erich Schlick MD Chairman of Supervisory Board
You’re viewing 5 of 17 executive team members. Get the full list »

Adrenomed Board Members (10)

Name Representing Role Since
Andreas Bergmann Ph.D Self Chief Scientific Officer & Board Member 000 0000
Bernd Wegener Adrenomed Co-Founder & Member of Supervisory Board 000 0000
Erich Schlick MD Adrenomed Chairman of Supervisory Board 000 0000
Metod Miklus Deutsche Biotech Innovativ Supervisory Board Member 000 0000
Priyanka Belawat Ph.D HBM Healthcare Investments Supervisory Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Adrenomed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adrenomed Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
HINKEL & Cie Corporation Minority 000 0000 000000 0
Deutsche Biotech Innovativ Corporation Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
KfW Group Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Adrenomed FAQs

  • When was Adrenomed founded?

    Adrenomed was founded in 2009.

  • Who is the founder of Adrenomed?

    Andreas Bergmann, Bernd Wegener, Gerald Moeller, and Frauke Hein Ph.D are the founders of Adrenomed.

  • Who is the CEO of Adrenomed?

    Richard Jones Ph.D is the CEO of Adrenomed.

  • Where is Adrenomed headquartered?

    Adrenomed is headquartered in Hennigsdorf, Germany.

  • What is the size of Adrenomed?

    Adrenomed has 26 total employees.

  • What industry is Adrenomed in?

    Adrenomed’s primary industry is Drug Discovery.

  • Is Adrenomed a private or public company?

    Adrenomed is a Private company.

  • What is Adrenomed’s current revenue?

    The current revenue for Adrenomed is 00000.

  • How much funding has Adrenomed raised over time?

    Adrenomed has raised $61.2M.

  • Who are Adrenomed’s investors?

    HINKEL & Cie, Deutsche Biotech Innovativ, HBM Healthcare Investments, HBM Partners, and KfW Group are 5 of 9 investors who have invested in Adrenomed.

  • Who are Adrenomed’s competitors?

    Altravax, Viriom, Cardior, AgomAb, and Cardurion are some of the 60 competitors of Adrenomed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »